Transcript
Announcer:
This is Clinician’s Roundtable on ReachMD. On this episode, we’ll hear from Dr. Javier Morales, Associate Clinical Professor of Medicine at the Barbara and Donald Zucker School of Medicine at Hofstra University and Northwell Health. He’ll be talking about the use of triple agonist therapies in obesity care. Here’s Dr. Morales now.
Dr. Morales:
Triple agonist therapies are quite useful because they further augment the weight loss that we see traditionally with the GLP-1 receptor agonists. Now, we have two systems in the brain when it comes to weight, and that is the POMC system and the CART system. These incretin-based therapies really have their effect in the arcuate nucleus in the area postrema and the nucleus solitarius in the brain, which are these areas that are responsible for appetite and satiety. Now, even though they are very sensitive to several different peptides, it's really interesting to see how this all plays out with these different peptides and which areas of the brain they're actually hitting, which results in even greater weight loss than either one agent or two agents alone.
Now, we have, in the obesity realm, a GLP-1 non-responder population. What that means is that we have people who are on GLP-1 receptor agonists who really don't lose much weight whatsoever. So perhaps using some of these other targets, they may experience a little bit more weight loss than those that were just on a GLP-1 receptor agonist alone.
So we have options available for our patients. But just as a reminder for our audience group, if you're managing patients with type 2 diabetes, you can use a GLP-1—it's very effective for controlling diabetes—but some people may lose a lot of weight, and some people may not lose a lot of weight.
Announcer:
That was Dr. Javier Morales discussing the use of triple agonist therapies in obesity care. To access this and other episodes in this series, visit Clinician’s Roundtable on ReachMD.com, where you can be part of the knowledge. Thanks for listening!